Istvan Redei
Hematology · Chicago, ILNPI 1306818109
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Gilead at 31.5% of the total. Reporting peaked in 2022 at $2,354 and has fallen 90.0% since, to $235 in 2023.
Across 134 payments — averaging $38.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Beigene USA, Inc.$679
- Novartis$372
- Seagen Inc.$320
- Bristol Myers Squibb$262
- Pfizer$236
- plus $2K from 26 others
Across 6 payments — averaging $8675.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- Janssen Research & Development, LLC$20K
What the payments were for
- Consulting fees$2,12542%
- Food & beverage$2,78955%
- Education$1944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 2 | $1,611 |
| Beigene USA, Inc. | 3 | $679 |
| Novartis | 18 | $372 |
| Seagen Inc. | 13 | $320 |
| Bristol Myers Squibb | 10 | $262 |
| Pfizer | 20 | $236 |
| Johnson & Johnson | 13 | $229 |
| Amgen | 9 | $227 |
| AstraZeneca | 5 | $220 |
| Genentech USA, Inc. | 7 | $142 |
| Jazz Pharmaceuticals Inc. | 2 | $100 |
| Astellas Pharma US Inc | 1 | $95 |
| Verastem, Inc. | 4 | $83 |
| Adaptive Biotechnologies Corporation | 1 | $57 |
| CTI Biopharma Corp. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Merck | 3 | $40 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Bayer | 2 | $34 |
| Aurobindo Pharma USA, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Sanofi | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Epizyme, Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $17 |
| Morphosys, US Inc. | 1 | $17 |
| Incyte Corporation | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,108 in reported general payments places this provider in the 60th percentile of 49 hematology providers in Illinois.
Other hematology in Chicago
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Nadia KhanChicago$66K
- Seema SinghalChicago$65K
- Olga FrankfurtChicago$49K
- Deborah KatzChicago$38K
- Martin TallmanChicago$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.